ES2578729T3 - Agente terapéutico para enfermedades relacionadas con el hígado - Google Patents

Agente terapéutico para enfermedades relacionadas con el hígado Download PDF

Info

Publication number
ES2578729T3
ES2578729T3 ES10812011.4T ES10812011T ES2578729T3 ES 2578729 T3 ES2578729 T3 ES 2578729T3 ES 10812011 T ES10812011 T ES 10812011T ES 2578729 T3 ES2578729 T3 ES 2578729T3
Authority
ES
Spain
Prior art keywords
therapeutic agent
related diseases
liver related
liver
vein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10812011.4T
Other languages
English (en)
Inventor
Akifumi Matsuyama
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Osaka Air Machine Service Ltd
Original Assignee
Osaka Air Machine Service Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osaka Air Machine Service Ltd filed Critical Osaka Air Machine Service Ltd
Application granted granted Critical
Publication of ES2578729T3 publication Critical patent/ES2578729T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Un agente terapéutico que comprende células progenitoras multilinaje derivadas de tejido adiposo para su uso en el tratamiento de una enfermedad relacionada con el hígado, donde el agente es para administrar a través de la vena porta, a través de una vena, a través de una arteria, o a través de un conducto biliar.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9

Claims (1)

  1. imagen1
ES10812011.4T 2009-08-28 2010-08-27 Agente terapéutico para enfermedades relacionadas con el hígado Active ES2578729T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2009198166 2009-08-28
JP2009198166 2009-08-28
PCT/JP2010/064623 WO2011024962A1 (ja) 2009-08-28 2010-08-27 肝臓関連疾患治療薬

Publications (1)

Publication Number Publication Date
ES2578729T3 true ES2578729T3 (es) 2016-07-29

Family

ID=43628060

Family Applications (1)

Application Number Title Priority Date Filing Date
ES10812011.4T Active ES2578729T3 (es) 2009-08-28 2010-08-27 Agente terapéutico para enfermedades relacionadas con el hígado

Country Status (5)

Country Link
US (1) US8784803B2 (es)
EP (1) EP2471542B1 (es)
JP (1) JP4965000B2 (es)
ES (1) ES2578729T3 (es)
WO (1) WO2011024962A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2600321T3 (es) * 2011-08-04 2017-02-08 Ethianum Betriebsgesellschaft Mbh & Co. Kg Medios para la regeneración del hígado
US9533013B2 (en) * 2013-03-13 2017-01-03 University Of North Carolina At Chapel Hill Method of treating pancreatic and liver conditions by endoscopic-mediated (or laparoscopic-mediated) transplantation of stem cells into/onto bile duct walls of particular regions of the biliary tree
WO2016167977A1 (en) 2015-04-14 2016-10-20 Mayo Foundation For Medical Education And Research Methods and materials for delivering agents to liver tissue
JP6923137B2 (ja) * 2018-06-15 2021-08-18 有限会社大阪空気機械サービス 組織治癒剤

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2237089T3 (es) * 1998-03-13 2005-07-16 Osiris Therapeutics, Inc. Usos para celulas madre mesenquimatosas humanas no autologas.
US20030082152A1 (en) * 1999-03-10 2003-05-01 Hedrick Marc H. Adipose-derived stem cells and lattices
KR100811995B1 (ko) * 2001-12-07 2008-03-10 사이토리 테라퓨틱스, 인크. 처리된 리포애스퍼레이트 세포로 환자를 치료하기 위한시스템 및 방법
ES2257225B1 (es) * 2006-02-17 2007-03-16 Grifols, S.A Preparacion terapeutica de fviia de muy alta pureza y metodo para su obtencion.
WO2007127698A2 (en) 2006-04-25 2007-11-08 Board Of Supervisors Of Louisiana State Universityand Agricultural And Mechanical College Adipose derived adult stem cells in hepatic regeneration
KR20090079187A (ko) 2006-08-03 2009-07-21 스마트 패키징 쏠루션즈 (에스피에스) 보안이 향상된 보안 증서, 특히 전자 패스포트
US9845458B2 (en) 2007-06-14 2017-12-19 Akifumi Matsuyama Multipotent progenitor cell derived from adipose tissue
JP5338322B2 (ja) 2008-01-11 2013-11-13 ダイキン工業株式会社 空気調和装置の室内ユニット

Also Published As

Publication number Publication date
JPWO2011024962A1 (ja) 2013-01-31
EP2471542B1 (en) 2016-04-27
EP2471542A4 (en) 2013-11-20
EP2471542A1 (en) 2012-07-04
US8784803B2 (en) 2014-07-22
JP4965000B2 (ja) 2012-07-04
US20120156181A1 (en) 2012-06-21
WO2011024962A1 (ja) 2011-03-03

Similar Documents

Publication Publication Date Title
CL2021003222A1 (es) (divisional de solicitud 400-2021) métodos para reducir la necesidad de revascularización arterial periférica en un sujeto tratado con estatinas.
SV2011003939A (es) Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades
CR11749A (es) Tratamiento de la disnea asociada con insuficiencia cardiaca aguda con relaxina
AR109605A2 (es) Método para tratar enfermedades vasculares periféricas, composición y utilización
AR072442A1 (es) Metodo para la terapia del cancer, uso, kit
NI200800169A (es) Uso de derivados de sulfamidas heterocíclicas benzo-fusionadas para el tratamiento del dolor
HK1203081A1 (en) Compositions and methods for enhanced generation of hematopoietic stem/progenitor cells
MX394764B (es) Metodos para reducir riesgo de evento cardiovascular en sujeto con terapia con estatina
EA201300121A1 (ru) Ингибитор дпп-4 в комбинации с дополнительным противодиабетическим агентом, таблетки, включающие указанные композиции, их применение и способ их получения
SG10201400685SA (en) Use Of Eicosapentaenoic Acid Ethyl Ester For Treating Hypertriglyceridemia
ECSP099436A (es) Acilaminopirazoles como inhibidores de fgfr
GT200600096A (es) Composicion farmaceutica para el tratamiento del cancer
UY31310A1 (es) Ácidos 6-fenilnicotínicos sustituidos y su uso
CL2011000099A1 (es) Uso de una beta-defensina humana en la manufactura de un medicamento que sirve para el tratamiento de una enfermedad intestinal inflamatoria.
WO2009004995A1 (ja) 生理活性物質を定着および発現させる方法
UY31189A1 (es) Compuestos heterocíclicos
PE20181332A1 (es) Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos
BR112015004643A2 (pt) métodos e composições para ressucitação hipotensiva
BR112012017994B8 (pt) composição líquida, uso de uma composição líquida, e, métodos para preparar uma composição líquida e para tratamento de um distúrbio
AR103415A1 (es) Tratamiento de pacientes pediátricos con diabetes mellitus de tipo 2
BR112013000613A2 (pt) composições secas e dispositivos que contêm tais composições secas
CO6531499A2 (es) Uso de ranolazina para el tratameinto de enfermedades cardiovasculares
RU2012131164A (ru) (метилсульфонил)этил-бензол-изоиндолиновые производные и их терапевтическое применение
AR084216A1 (es) Composiciones y metodos para tratar el cancer usando un inhibidor de pi3k e inhibidor de mek, kit
IT1398773B1 (it) Sequenze oligonucleotidiche inibitrici dell'espressione della chimera ciclina d1/trop2 e loro uso in campo medico.